Christian Rohlff
Chief Executive Officer Oxford BioTherapeutics
Christian has been CEO of Oxford BioTherapeutics since founding the company and acquiring key technology, bioinformatics data and intellectual property. He brings more than 20 years of experience in the international biotechnology industry. Following his PhD in Pharmacology from Georgetown University, Christian worked at the US National Cancer Institute in Bethesda, Maryland. Prior to founding OBT, he held a number of positions of increasing seniority with Oxford Glycosciences, and led the company’s partnerships in oncology with Pfizer, GSK, Bayer, Wyeth, Takeda, Oxford University and the FDA.
Seminars
Wednesday 25th February 2026
Showcasing Tubulin Inhibitor Payload Innovation to Develop Novel ADCs & Subvert Patient Resistance to Established Mechanisms
11:30 am
- Weighing up novel payload development through evolving existing payload classes versus pursuing novel mechanisms
- Leveraging new and advanced tools to investigate novel tubulin payload development
- Contextualising payload innovation through ADC programmes and understanding significance for nextgeneration ADC development
